EricaLMayerMD

Oncology • Boston, MA

Assistant Professor, Medicine-Brigham & Women's Hospital, Harvard Medical School

Join to view full profile

Dr. Mayer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Mayer's full profile

Already have an account?

Office
450 Brookline Ave
Boston, MA 02215
Phone+1 617-632-3800

Fax+1 617-632-1930
Is this information wrong?

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2003 - 2006
Brigham and Women's HospitalResidency, Internal Medicine, 2000 - 2003
Harvard Medical SchoolClass of 2000

Certifications & Licensure

MA State Medical License 2002 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer Start of enrollment: 2007 Jul 01
Completed
Phase 1
Hypertension in Breast Cancer Patients Receiving Bevacizumab Start of enrollment: 2008 Jan 01
Terminated
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 3
Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer Start of enrollment: 2010 Sep 01
Terminated
Phase 2
Eribulin in HER2 Negative Metastatic BrCa Start of enrollment: 2013 May 01
Completed
Phase 2
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women Start of enrollment: 2014 Mar 11
Completed
Phase 2
Cisplatin vs Paclitaxel for Triple Negative Breast Cancer Start of enrollment: 2014 Apr 01
Completed
Phase 2
Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer Start of enrollment: 2014 Jan 01
Completed
Phase 2
Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer Start of enrollment: 2015 Jun 01
Terminated
Phase 1, Phase 2
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Recruiting
Phase 3
Palbociclib After CDK and Endocrine Therapy (PACE) Start of enrollment: 2017 Sep 05
Active, not recruiting
Phase 2
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer Start of enrollment: 2020 Dec 18
Recruiting
Phase 2
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer Start of enrollment: 2023 Oct 05
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Horm...
Erica L Mayer, Yue Ren, Nikhil Wagle, Reshma Mahtani, Cynthia Ma, Angela DeMichele, Massimo Cristofanilli, Jane Meisel, Kathy D Miller, Yara Abdou, Elizabeth C Riley, ...> ;Journal of Clinical Oncology. 2024 Mar 21
Disease-free survival as a surrogate for overall survival in HR+/HER2- early breast cancer: A correlation analysis.
Michael Untch, David Pérol, Erica L Mayer, Javier Cortes, Arnd Nusch, David Cameron, Carlos Barrios, Thomas Delea, Andrii Danyliv, Namita Mishra, Rhea Gupta, Purnima P...> ;European Journal of Cancer. 2024 May 1
1 citations
Association of N-terminal Pro-Brain natriuretic peptide with survival among US cancer survivors.
Cao, C., Yang, L., Nohria, A., Mayer, E., Partridge, A., Ligibel, J.> ;Journal of the National Cancer Institute. 2024 Feb 1
Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131.
Karen L Smith, Fengmin Zhao, Ingrid A Mayer, Amye J Tevaarwerk, Sofia F Garcia, Carlos L Arteaga, William F Symmans, Ben H Park, Brian L Burnette, Della F Makower, Mar...> ;Cancer. 2024 May 15
Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance.
Ahmed, S., Albert E Kim, Kevin W Lou, Anita Giobbie-Hurder, Ken Chang, Mishka Gidwani, Katharina Hoebel, Jay B Patel, Mason C Cleveland, Praveer Singh, Christopher P B...> ;Neuro-Oncology. 2024 May 3
1 citations
Taxanes for the treatment of breast cancer during pregnancy: an international cohort study.
Ferrigno Guajardo, A., Vaca-Cartagena, B., Mayer, E., Bousrih, C., Oluchi, O., Saura, C., Peccatori, F., Muñoz-Montaño, W., Cabrera-Garcia, A., Lambertini, M., Corrale...> ;Journal of the National Cancer Institute. 2024 Feb 8
A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.
Erica L Mayer, Nabihah Tayob, Siyang Ren, Jennifer J Savoie, David R Spigel, Howard A Burris 3rd, Paula D Ryan, Lyndsay N Harris, Eric P Winer, Harold J Burstein> ;Breast Cancer Research and Treatment. 2024 Feb 1
ASO Visual Abstract: Racial and Ethnic Disparities in Outcomes after Breast-Conserving Therapy and Endocrine Therapy for DCIS-A Post Hoc Analysis of the NSABP B-35 Ran...
Olga Kantor, Tari A King, Alyssa Jones, Charity Glass, Saskia J Leonard, Esther R Ogayo, Erica L Mayer, Mariana Chavez-MacGregor, Lisa A Newman, Rachel A Freedman, Eli...> ;Annals of Surgical Oncology. 2024 Feb 1
Racial and Ethnic Disparities in Outcomes After Breast-Conserving Therapy and Endocrine Therapy for DCIS: A Post-Hoc Analysis of the NSABP B-35 Randomized Clinical Trial.
Olga Kantor, Tari A King, Alyssa Jones, Charity Glass, Saskia J Leonard, Esther R Ogayo, Erica L Mayer, Mariana Chavez-MacGregor, Lisa A Newman, Rachel A Freedman, Eli...> ;Annals of Surgical Oncology. 2023 Dec 1
ASO Visual Abstract: Racial Disparities in Locoregional Recurrence in Postmenopausal Patients with Stage I-III, Hormone Receptor-Positive Breast Cancer Enrolled in the...
Charity C Glass, Robert M Pride, Rachel A Freedman, Erica L Mayer, Esther R Ogayo, Mariana Chavez-MacGregor, Tari A King, Elizabeth A Mittendorf, Olga Kantor> ;Annals of Surgical Oncology. 2024 Jan 1
Racial Disparities in Locoregional Recurrence in Postmenopausal Patients with Stage I-III, Hormone Receptor-Positive Breast Cancer Enrolled in the NSABP B-42 Clinical ...
Charity C Glass, Robert M Pride, Rachel A Freedman, Erica L Mayer, Esther R Ogayo, Mariana Chavez-MacGregor, Tari A King, Elizabeth A Mittendorf, Olga Kantor> ;Annals of Surgical Oncology. 2023 Dec 1
1 citations
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.
Lauren Lenz, Chris Neff, Cara Solimeno, Elizabeth S Cogan, Vandana G Abramson, Judy C Boughey, Carla Falkson, Matthew P Goetz, James M Ford, William J Gradishar, Rache...> ;Breast Cancer Research and Treatment. 2023 Nov 1
1 citations
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial.
Georg Pfeiler, Dominik Hlauschek, Erica L Mayer, Christine Deutschmann, Stephanie Kacerovsky-Strobl, Miguel Martin, Jane Lowe Meisel, Nicholas Zdenkowski, Sibylle Loib...> ;Journal of Clinical Oncology. 2023 Nov 20
6 citations
Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results.
Priscilla K Brastianos, Albert E Kim, Anita Giobbie-Hurder, Eudocia Q Lee, Nancy U Lin, Beth Overmoyer, Patrick Y Wen, Lakshmi Nayak, Justine V Cohen, Jorg Dietrich, A...> ;Nature Medicine. 2023 Jul 1
8 citations
Single duplex DNA sequencing with CODEC detects mutations with high sensitivity.
Jin H Bae, Ruolin Liu, Eugenia Roberts, Erica Nguyen, Shervin Tabrizi, Justin Rhoades, Timothy Blewett, Kan Xiong, Gregory Gydush, Douglas Shea, Zhenyi An, Sahil Patel...> ;Nature Genetics. 2023 May 1
6 citations
Design of SERENA-6, a phase III switching trial of camizestrant in-mutant breast cancer during first-line treatment.
Nicholas Turner, Cynthia Huang-Bartlett, Kevin Kalinsky, Massimo Cristofanilli, Giampaolo Bianchini, Stephen Chia, Hiroji Iwata, Wolfgang Janni, Cynthia X Ma, Erica L ...> ;Future Oncology. 2023 Mar 1
2 citations
New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer.
Jamie O Brett, Erica L Mayer> ;Current Treatment Options in Oncology. 2023 Jun 1
8 citations
Racial and Ethnic Disparities in Locoregional Recurrence Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer: A Post Hoc Analysis of the TAILORx...
Olga Kantor, Tari A King, Rachel A Freedman, Erica L Mayer, Mariana Chavez-MacGregor, Larissa A Korde, Joseph A Sparano, Elizabeth A Mittendorf> ;JAMA Surgery. 2023 Jun 1
3 citations
Clonal hematopoiesis in older patients with breast cancer receiving chemotherapy.
Christina Mayerhofer, Mina S Sedrak, Judith O Hopkins, Tianyu Li, Nabihah Tayob, Meredith G Faggen, Natalie F Sinclair, Wendy Y Chen, Heather A Parsons, Erica L Mayer,...> ;Journal of the National Cancer Institute. 2023 Aug 8
8 citations
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer.
Albert Grinshpun, Sara M Tolaney, Harold J Burstein, Rinath Jeselsohn, Erica L Mayer> ;NPJ Breast Cancer. 2023 Mar 22
10 citations
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial.
Tufia C Haddad, Vera J Suman, Antonino B D'Assoro, Jodi M Carter, Karthik V Giridhar, Brendan P McMenomy, Katelyn Santo, Erica L Mayer, Meghan S Karuturi, Aki Morikawa...> ;JAMA Oncology. 2023 Jun 1
3 citations
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.
Heather A Parsons, Timothy Blewett, Xiangying Chu, Sainetra Sridhar, Katheryn Santos, Kan Xiong, Vandana G Abramson, Ashka Patel, Ju Cheng, Adam Brufsky, Justin Rhoade...> ;Medrxiv. 2023 Mar 8
4 citations
What's the reality for CDK4/6 inhibitors: Clinical trials or real-world evidence?
Dario Trapani, Erica L Mayer> ;Cancer. 2023 Apr 1
5 citations
Emerging Targeted Therapies for Early Breast Cancer.
Ilana Schlam, Stefania Morganti, Filipa Lynce, Dario Trapani, Erica L Mayer, Ana C Garrido-Castro, Ada Waks, Sara M Tolaney, Tarantino, P.> ;Drugs. 2022 Sep 1
1 citations
'ADVANCE' (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer.
Rachel A Freedman, Tianyu Li, Mina S Sedrak, Judith O Hopkins, Nabihah Tayob, Meredith G Faggen, Natalie F Sinclair, Wendy Y Chen, Heather A Parsons, Erica L Mayer, Pa...> ;Journal of Geriatric Oncology. 2023 Jan 1
Join now to see all

Lectures

TBCRC 030: A randomized phase II study of preoperative cisplatin versus paclitaxel in TNBCâ€”Evaluating the homologous recombination deficiency (HRD) biomarker.
2019 ASCO Annual Meeting - 6/1/2019
Cracking the Code: Predicting Late Risk in Hormone-Receptor-Positive Disease
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2- metastati...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Optimizing Treatment for Older Patients with HR+ Low-Risk Breast CancerJanuary 5th, 2023
No Benefit of Palbociclib with Fulvestrant Beyond Progression on Prior CDK4/6 InhibitionDecember 20th, 2022
Targeted Therapies for Metastatic Breast Cancer— Here's What You Should KnowSeptember 7th, 2022
Join now to see all